What is AngioScore?
AngioScore is an endovascular company based in Fremont, California, focused on creating innovative angioplasty catheters for treating coronary and peripheral artery disease. Its flagship product, the AngioSculpt® Scoring Balloon Catheter, features a unique system of nitinol-scoring elements integrated with a traditional balloon catheter. This design concentrates dilating force to minimize balloon slippage and improve luminal expansion in stenotic arteries, offering a distinct advantage in interventional cardiology.
How much funding has AngioScore raised?
AngioScore has raised a total of $12M across 1 funding round:
Private Equity
$12M
Private Equity (2012): $12M with participation from Pelion Venture Partners, California Technology Ventures, LLC, Telegraph Hill Partners, Saints capital, and QuestMark Partners
Key Investors in AngioScore
Pelion Venture Partners
Pelion Venture Partners is a venture capital firm that manages a portfolio of funds, offering investment solutions tailored for clients seeking diversified investment opportunities. They aim to support clients in achieving their financial objectives through a managed fund approach.
California Technology Ventures, LLC
California Technology Ventures specializes in direct investments in technology and life science companies, focusing on building world-class enterprises. They provide capital, resources, and strategic guidance to entrepreneurs.
Telegraph Hill Partners
Telegraph Hill Partners invests in commercial stage life science, medical technology, and healthcare companies, providing strategic backing for growth and market expansion.
What's next for AngioScore?
With a substantial enterprise-level funding round and a recent strategic investment, AngioScore is positioned for significant scaling and product development. The company's focus on its proprietary scoring balloon technology suggests a strategy aimed at capturing a larger share of the interventional cardiology market. Future endeavors will likely involve expanding clinical applications, further product innovation, and potentially broader market adoption, leveraging the recent capital to enhance its competitive edge and drive revenue growth.
See full AngioScore company page
